Charles Schwab’s Vor Biopharma VOR Stock Holding History

Charles Schwab’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$396K	Buy	+22,216	New	+$313K	﹤0.01%	3176
2024 Q4	–	Sell	-890	Closed	-$12.5K	–	3520
2024 Q3	$12.5K	Hold	890	–	–	﹤0.01%	3499
2024 Q2	$17.8K	Sell	890 -4,306	-83%	-$139K	﹤0.01%	3596
2024 Q1	$246K	Hold	5,196	–	–	﹤0.01%	3207
2023 Q4	$234K	Hold	5,196	–	–	﹤0.01%	3257
2023 Q3	$220K	Hold	5,196	–	–	﹤0.01%	3269
2023 Q2	$321K	Buy	5,196 +4,306	+484%	+$393K	﹤0.01%	3210
2023 Q1	$95.7K	Buy	890 +346	+64%	+$38.3K	﹤0.01%	3254
2022 Q4	$72.3K	Hold	544	–	–	﹤0.01%	3300
2022 Q3	$44K	Sell	544 -1,530	-74%	-$150K	﹤0.01%	3361
2022 Q2	$207K	Sell	2,074 -2,605	-56%	-$267K	﹤0.01%	3240
2022 Q1	$566K	Buy	4,679 +62	+1%	+$10.6K	﹤0.01%	3064
2021 Q4	$1.07M	Buy	4,617 +144	+3%	+$41.5K	﹤0.01%	2882
2021 Q3	$1.4M	Buy	4,473 +1,021	+30%	+$304K	﹤0.01%	2771
2021 Q2	$1.29M	Sell	3,452 -210	-6%	-$104K	﹤0.01%	2845
2021 Q1	$3.16M	Buy	+3,662	New	+$3.1M	﹤0.01%	2518

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab's VOR Position: Q1 2026 in Review

Charles Schwab opened a new position in Vor Biopharma (VOR) in Q1 2026: 22,216 shares worth $396K. The stake represents ﹤0.01% of the portfolio and ranks #3176 among its holdings. This is a return to the name: Charles Schwab previously reported a position in VOR as recently as Q3 2024.

Charles Schwab first reported a position in VOR in Q1 2021 and has held it in 16 quarters since. The position peaked at $3.16M in Q1 2021. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Charles Schwab held 22,216 shares of Vor Biopharma worth $396K as of Q1 2026.
Vor Biopharma was a new Charles Schwab position in Q1 2026.
Vor Biopharma made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3176 holding.
Charles Schwab first reported a position in Vor Biopharma in Q1 2021 and has held it in 16 quarters since.
Charles Schwab's Vor Biopharma position peaked at $3.16M in Q1 2021.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.